BioWorld

April 3, 2008

Medarex Shares Take Hit Amid Pfizer's Halted Melanoma Trial

Medarex shares plummeted Wednesday as partner Pfizer Inc. unexpectedly halted a Phase III trial of potential melanoma treatment tremelimumab. (BioWorld Today) Read More

Trial Data Could Prompt ISTA to Tweak Xibrom Formulations

Papers Agree on Lung Cancer Risk Genes, Disagree on Why

FDA Panel Supports Use of Noninferiority Studies for CAP

Genta Cutting Staff, Selling Ganite in Wake of Rejection

Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

SERCA inhibitor shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...